Jejunum

Penn Highlands Healthcare Marks 100 Bariatric Surgeries at Penn Highlands DuBois

Retrieved on: 
Wednesday, May 3, 2023

In the past nine months, Mrs. Gray has lost 105 pounds as a result of the bariatric surgery she had at Penn Highlands DuBois in July 2022.

Key Points: 
  • In the past nine months, Mrs. Gray has lost 105 pounds as a result of the bariatric surgery she had at Penn Highlands DuBois in July 2022.
  • Megan P. Lundgren, MD, is a general surgeon who specializes in bariatric and minimally invasive surgery at Penn Highlands Bariatric and General Surgery in DuBois.
  • Dr. Lundgren, who recently performed the 100th bariatric surgery in DuBois, established the bariatric program in 2021 at Penn Highlands Healthcare in Northwestern/Central Pennsylvania.
  • “Penn Highlands Healthcare Bariatric Surgery is a blessing!”
    Penn Highlands Healthcare was officially formed in 2011, and is comprised of eight hospitals – Penn Highlands Brookville, Penn Highlands Clearfield, Penn Highlands Connellsville, Penn Highlands DuBois, Penn Highlands Elk, Penn Highlands Huntingdon, Penn Highlands Mon Valley, Penn Highlands Tyrone -- that have served area communities for the past 100+ years.

New to The Street TV Announces Four Corporate Interviews on its 387th Show Airing on the Fox Business Network, Tonight, Monday, September 19, 2022, at 10:30 PM PT

Retrieved on: 
Monday, September 19, 2022

Tonight, New to The Street TV's Host Jane King welcomes back Sharif El-Gamal, Chief Executive Officer at Soho Properties .

Key Points: 
  • Tonight, New to The Street TV's Host Jane King welcomes back Sharif El-Gamal, Chief Executive Officer at Soho Properties .
  • The capital markets dried up after the recent downturn in the investment markets and overall permission from investors and governmental organizations.
  • The interview with Mary Spio, CEO/Founder at CEEK VR (CRYPTO: $CEEK) ($CEEK) , is re-airing on tonights New to The Street TV.
  • FMW's New to The Street / Newsmax TV broadcasting platform airs its syndication on Sundays at 10 -11 AM ET.

New to The Street TV Announces Featured Guest Interviews, Airing on Bloomberg TV as a Sponsored Program, Saturday, August 27, 2022, at 6:30 PM ET

Retrieved on: 
Friday, August 26, 2022

(TSXV: LFST (FRANKFURT: M5B) (OTCMKTS: NXTTF) joins the New to The Street TV from the Nasdaq Marketplace studio explaining to Host Jane King the Company.

Key Points: 
  • (TSXV: LFST (FRANKFURT: M5B) (OTCMKTS: NXTTF) joins the New to The Street TV from the Nasdaq Marketplace studio explaining to Host Jane King the Company.
  • The unique make-up of CELLF allows it to pass through the digestive system and be absorbed into the mid-small intestine (jejunum) and distributed to cells.
  • As a nutraceutical gel with a buttery-type consistency, the product contains nutrient doses similarly used in other non-related clinical studies.
  • FMWs New to The Street / Newsmax TV broadcasting platform airs its syndication on Sundays at 10 -11 AM ET.

Evelo Biosciences Announces Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

Retrieved on: 
Thursday, March 24, 2022

CAMBRIDGE, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today reported financial results and business highlights for the fourth quarter and full year 2021.

Key Points: 
  • ET
    CAMBRIDGE, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing SINTAX medicines as a new modality of orally delivered treatments for inflammatory disease, today reported financial results and business highlights for the fourth quarter and full year 2021.
  • The primary unmet need in psoriasis is for this segment of patients, said Simba Gill, Ph.D., Chief Executive Officer of Evelo.
  • An ad hoc analysis comparing the combined EDP1815 group also showed a statistically significant improvement over placebo in rates of PASI-50 response.
  • ET today to review fourth quarter and full year 2021 highlights.

Rani Therapeutics Unveils High-Capacity RaniPill™ Device For Oral Delivery of Biologics; Reports Preliminary 2021 Consolidated Financial Results

Retrieved on: 
Wednesday, February 23, 2022

SAN JOSE, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics, today announced the development of a high-capacity oral biologics device known as the RaniPill™ HC (High Capacity), capable of delivering up to a 500%-plus higher drug payload than Rani’s existing oral biologics capsule. In preclinical testing, RaniPill™ HC demonstrated successful delivery of adalimumab and achieved high bioavailability.

Key Points: 
  • A copy of the data is available on the Presentations page of Rani Therapeutics investor relations website: https://ir.ranitherapeutics.com/news-events/presentations .
  • Ranis preliminary consolidated financial results for the three months and year ended December 31, 2021 are presented below, and the results are subject to finalization of the Companys customary quarterly and annual financial close processes.
  • Further, this preliminary estimate is not a comprehensive statement or estimate of our consolidated financial results or financial condition as of and for the year ended December31, 2021.
  • The ranges for the preliminary estimated consolidated financial results described above constitute forward-looking statements, are subject to change, and our actual financial results may differ from such preliminary estimates and such differences could be material.

Enteral Collagen Peptide Protein Market - Global Opportunity Analysis and Industry Forecast, 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 2, 2021

The "Enteral Collagen Peptide Protein Market by Form, Age Group and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Enteral Collagen Peptide Protein Market by Form, Age Group and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global enteral collagen peptide protein market was valued at $14,586 thousand in 2020, and is projected to reach $25,811 thousand by 2030, registering a CAGR of 7.2% from 2021-2030.
  • The growth of the global enteral collagen peptide protein market is majorly driven by a rise in the prevalence of chronic illness such osteoarthritis and cardiovascular diseases and increase in application of enteral collagen peptide proteins in the healthcare sector.
  • However, poor demand and lack of awareness of enteral collagen peptide protein products in underdeveloped countries hamper the market growth.